First Trust Nasdaq Pharmaceuticals ETF
FTXH
9 hedge funds and large institutions have $1.31M invested in First Trust Nasdaq Pharmaceuticals ETF in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
8% more capital invested
Capital invested by funds: $1.22M → $1.31M (+$94K)
1.92% more ownership
Funds ownership: 16.5% → 18.42% (+1.9%)
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$287K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$10.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.46K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$21 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMFS
Squar Milner Financial Services
Irvine,
California
|
-$119K |
| 2 |
Jane Street
New York
|
-$39.7K |
| 3 |
LPL Financial
San Diego,
California
|
-$8.26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $592K | -$39.7K | -1,927 | -6% |
|
|
2
LPL Financial
San Diego,
California
| $307K | -$8.26K | -401 | -3% |
|
|
3
Citadel Advisors
Miami,
Florida
| $284K | +$287K | +13,923 | New |
|
|
4
Bank of America
Charlotte,
North Carolina
| $53K | +$10.3K | +500 | +24% |
|
|
5
UBS Group
Zurich,
Switzerland
| $38K | +$5.46K | +265 | +17% |
|
|
AG
6
Advisor Group
Phoenix,
Arizona
| $18K | – | – | – |
|
|
LTFS
7
Ladenburg Thalmann Financial Services
Miami,
Florida
| $14K | – | – | – |
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $8K | – | – | – |
|
|
SMFS
9
Squar Milner Financial Services
Irvine,
California
| – | -$119K | -5,640 | Closed |
|
|
10
Wells Fargo
San Francisco,
California
| – | +$21 | +1 | +100% |
|
FTXH Hedge Fund Activity: Q3 2019 in Review
9 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q3 2019, worth a combined $1.31M — up 7.7% from $1.22M a quarter earlier.
Fund positioning in FTXH was balanced in Q3 2019: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $287K. The largest seller was Squar Milner Financial Services, exiting entirely with an estimated $119K sold.
- 9 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $1.31M of First Trust Nasdaq Pharmaceuticals ETF stock for Q3 2019, up 7.7% quarter-over-quarter.
- 1 fund opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q3 2019 and 1 closed out, a net change of 0 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q3 2019 was Citadel Advisors, an estimated $287K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q3 2019 was Squar Milner Financial Services, an estimated $119K sold.
Based on aggregated 13F filings for Q3 2019.